The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: analysis of the CREDENCE trial de Zeeuw, D., Arnott, C., Li, J., Cannon, C. P., Neuen, B. L., Heerspink, H. L., Neal, B., Charytan, D. M., Bakris, G., Chang, T., Rosenthal, N., Zinman, B., Perkovic, V., Jardine, M. J., Mahaffey, K. W. SPRINGER. 2020: S61–S62

View details for Web of Science ID 000565776600123